Speakers:

• Patricia Bradford, Antimicrobial Development Specialists LLC (US)
• Alita Miller, Entasis Therapeutics (US)

Moderator: Michael Mourez, École d’Ingénieurs de PURPAN (France)

Presentations:

Screen to pre-clinical candidate (Alita Miller):

• Discovery strategies
• Hit-to-lead generation
• MOA studies
• Spectrum of activity
• Resistance studies
• In vitro toxicity assessments
• PK/PD characterization

Pre-clinical candidate to phase 1 (Patricia Bradford):

• Non-clinical package requirements for first-in-human studies
• Dose selection
• Non-clinical toxicity
• CMC considerations
• Regulatory process/pathways

The presentations were followed by a Q&A session.

This live webinar including interactive Q&A session was broadcast on 25 February 2021.

If you have questions or comments, please let us know: revive@gardp.org.